Review articlePlatinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives

Add time:08/23/2019    Source:sciencedirect.com

Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted.

We also recommend Trading Suppliers and Manufacturers of cis-Dimethyl(N,N,N',N'-tetramethylethylenediamine)palladium(II), 99% (cas 113822-11-0). Pls Click Website Link as below: cas 113822-11-0 suppliers

Prev:ReviewComprehensive review on tumour active palladium compounds and structure–activity relationships
Next:Palladium(II) complexes of 2-, 3-, and 4-quinolinyl(diphenyl)phosphane and di-(3-quinolinyl)phenylphosphane: Synthesis, characterization, and catalytic screening)